The internal perspective

Mathias Uhlén,

Professor of Microbiology, KTH Royal Institute of Technology in Stockholm

Mathias Uhlen  research is focused on protein science, antibody engineering and precision medicine and ranges from basic research in human and microbial biology to more applied research, including clinical applications in cancer, infectious diseases, cardiovascular diseases, autoimmune diseases and neurobiology. His research has resulted in 850 publications and more the 100,000 citations (h-index 140) according to Google Scholar.

He is co-founder of 21 biotech companies. Since 2003, he has led an international effort to systematically map the human proteome to create a Human Protein Atlas using antibodies and various omics technologies. He is member of the National Academy of Engineering (NAE) in USA, the Royal Swedish Academy of Science (KVA), the Swedish Academy of Engineering Science (IVA) and the European Molecular Biology Organization (EMBO).

He is member of the board of the Swedish Research Council (VR) and the Erling Persson Foundation. He was the President of the European Federation of Biotechnology 2014-2020 and he was the Founding Director of the Science for Life Laboratory (SciLifeLab), a Swedish national center for molecular bioscience (2010-2015).

Ulf Landegren  

Professor of Molecular Medicine, Uppsala University

Ulf Landegren, MD PhD, is professor of molecular medicine at Uppsala University in Sweden. His lab is developing molecular tools, including padlock probes and proximity ligation assays for nucleic acid and protein analysis, respectively. Ulf is a member of EMBO and the Royal Swedish Academy of Sciences, and of several academic and industrial boards and advisory boards.

He has authored 230 peer-reviewed publications, and some 55 patents or applications. His lab has given rise to numerous spin-out companies with a combined staff of more than 900 people, including Olink Proteomics, Navinci, Rarity, Readily and SampleFacts. Technologies from his lab have also been licensed to many leading international biotech and diagnostic companies.

Åsa Manelius

Therapy Area Lead, Respiratory & Immunology, Global Supply Chain & Strategy, AstraZeneca 

Åsa Manelius, Therapy Area Lead, Respiratory & Immunology, is since July 2023 responsible for global supply chains for manufacturing in the therapeutic area of respiratory and immunology within AstraZeneca. 
In December 2019, she joined AstraZeneca as General Manager Sweden Biologics, AstraZeneca's new factory to manage the company's rapidly growing portfolio of biologics and the need for increased internal production capacity.

Åsa has over 25 years of experience in the Life Science industry and has previously held positions in general management as Managing Director and several executive and senior leader and management roles in pharmaceutical and medical device manufacturing operations including development and supply chain.

During 2010-2019 Åsa was Managing Director and Site Lead at Biora AB, and she has also previously worked for Pfizer’s Biologics manufacturing site in Sweden. Åsa holds a Tekn. Lic. degree in Biotechnology and Biochemical Engineering and M.Sc. degree in Chemical Engineering from Lund University.

Åsa represents AstraZeneca AB in several boards, such as IKEM, Innovation and Chemical Industries in Sweden and is also a member of the Board of Directors in the Confederation of Swedish Enterprise.